Jiangsu Jibeier Pharmaceutical Co., Ltd. (SHA:688566)
27.68
-0.26 (-0.93%)
Feb 4, 2026, 11:29 AM CST
SHA:688566 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 737.7 | 847.48 | 694.87 | 903.9 | 1,025 | 1,287 |
Trading Asset Securities | 151.01 | 56 | 35 | 90 | 200 | - |
Cash & Short-Term Investments | 888.72 | 903.48 | 729.87 | 993.9 | 1,225 | 1,287 |
Cash Growth | -7.52% | 23.79% | -26.57% | -18.87% | -4.84% | 565.71% |
Accounts Receivable | 384.22 | 300.75 | 369.15 | 216.21 | 146.6 | 187.49 |
Other Receivables | 0.31 | 0.05 | 0.03 | 0.02 | - | - |
Receivables | 384.53 | 300.8 | 369.17 | 216.23 | 146.6 | 187.49 |
Inventory | 36.19 | 30.7 | 29.51 | 32.66 | 31.83 | 32.11 |
Other Current Assets | 7.18 | 69.46 | 2.59 | 13.98 | 2.62 | 2.93 |
Total Current Assets | 1,317 | 1,304 | 1,131 | 1,257 | 1,406 | 1,510 |
Property, Plant & Equipment | 1,020 | 986.86 | 832.49 | 552.21 | 271.51 | 156.8 |
Long-Term Investments | 81.96 | 79.79 | 126.19 | 61.74 | 56.63 | - |
Other Intangible Assets | 58.59 | 56.69 | 58.2 | 59.74 | 61.28 | 63.03 |
Long-Term Deferred Tax Assets | 21.44 | 17.93 | 16.13 | 15.59 | 11.72 | 10.92 |
Long-Term Deferred Charges | 55.46 | 32.14 | 1.13 | 2.18 | 3.25 | 4.32 |
Other Long-Term Assets | 50.58 | 49.69 | 44.38 | 16.34 | 8.21 | 2.31 |
Total Assets | 2,640 | 2,528 | 2,210 | 1,965 | 1,819 | 1,747 |
Accounts Payable | 72.34 | 97.15 | 91.22 | 101.67 | 69.92 | 25.81 |
Accrued Expenses | 20.4 | 45.73 | 86.79 | 53.49 | 35.3 | 43.06 |
Short-Term Debt | 19.81 | 20.83 | 9.91 | - | - | - |
Current Income Taxes Payable | 33.95 | 2.01 | 0.19 | 6.09 | 5.19 | 5.29 |
Current Unearned Revenue | 2.28 | 0.95 | 1.81 | 3.42 | 1.51 | 1.01 |
Other Current Liabilities | 29.76 | 18.53 | 20.39 | 16.69 | 12.14 | 8.85 |
Total Current Liabilities | 178.54 | 185.19 | 210.31 | 181.36 | 124.06 | 84.01 |
Long-Term Unearned Revenue | 58.57 | 58.59 | 59.04 | 58.85 | 59.7 | 60.27 |
Long-Term Deferred Tax Liabilities | 3.93 | 3.25 | 3.25 | 3.4 | - | - |
Other Long-Term Liabilities | 26.64 | 26.64 | 26.64 | 26.64 | 26.64 | 26.64 |
Total Liabilities | 269.87 | 273.68 | 299.25 | 270.24 | 210.4 | 170.92 |
Common Stock | 199.43 | 199.43 | 189.08 | 186.94 | 186.94 | 186.94 |
Additional Paid-In Capital | 1,316 | 1,299 | 1,082 | 1,042 | 1,021 | 1,013 |
Retained Earnings | 842.97 | 749.77 | 633.4 | 459.17 | 394.24 | 369.07 |
Total Common Equity | 2,358 | 2,249 | 1,905 | 1,688 | 1,602 | 1,569 |
Minority Interest | 11.65 | 5.23 | 5.58 | 5.9 | 6.31 | 6.86 |
Shareholders' Equity | 2,370 | 2,254 | 1,910 | 1,694 | 1,608 | 1,576 |
Total Liabilities & Equity | 2,640 | 2,528 | 2,210 | 1,965 | 1,819 | 1,747 |
Total Debt | 22.01 | 20.83 | 9.91 | - | - | - |
Net Cash (Debt) | 866.71 | 882.65 | 719.96 | 993.9 | 1,225 | 1,287 |
Net Cash Growth | -9.52% | 22.60% | -27.56% | -18.87% | -4.84% | 565.71% |
Net Cash Per Share | 4.35 | 4.55 | 3.84 | 5.33 | 6.50 | 7.64 |
Filing Date Shares Outstanding | 199.43 | 199.43 | 189.08 | 186.94 | 186.94 | 186.94 |
Total Common Shares Outstanding | 199.43 | 199.43 | 189.08 | 186.94 | 186.94 | 186.94 |
Working Capital | 1,138 | 1,119 | 920.84 | 1,075 | 1,282 | 1,426 |
Book Value Per Share | 11.82 | 11.28 | 10.07 | 9.03 | 8.57 | 8.40 |
Tangible Book Value | 2,264 | 2,192 | 1,847 | 1,629 | 1,541 | 1,506 |
Tangible Book Value Per Share | 11.35 | 10.99 | 9.77 | 8.71 | 8.24 | 8.06 |
Buildings | - | 142.66 | 142.66 | 142.52 | 142.52 | 142.52 |
Machinery | - | 75.26 | 74.81 | 73.37 | 72.78 | 67.24 |
Construction In Progress | - | 917.62 | 754.62 | 466.36 | 175.48 | 55.13 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.